PEPGEN INC. Depreciation
PEPGEN INC. (PEPG) reported Depreciation of $572.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- PEPGEN INC. depreciation for the quarter ending 2026-06-30 was $253.00K, a 24.25% decline year-over-year.
- PEPGEN INC. depreciation for the quarter ending 2026-03-31 was $319.00K, a 17.78% decline year-over-year.
- PEPGEN INC. depreciation for the quarter ending 2025-12-31 was $336.00K, a 11.58% decline year-over-year.
- PEPGEN INC. depreciation for the quarter ending 2025-09-30 was $339.00K, a 10.55% decline year-over-year.
- PEPGEN INC. depreciation for fiscal 2025 was $1.40M, a 7.18% decline from fiscal 2024.
- PEPGEN INC. depreciation for fiscal 2024 was $1.50M, a 27.11% increase from fiscal 2023.
- PEPGEN INC. depreciation for fiscal 2023 was $1.18M, a 140.16% increase from fiscal 2022.
- PEPGEN INC. depreciation for fiscal 2022 was $493.00K, a 176.97% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $572.00K 10-Q · filed 2026-08-06 | $908.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $319.00K 10-Q · filed 2026-05-12 | $655.00K derived: sum of 2 quarters · filed 2026-05-12 | $994.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $675.00K derived: sum of 2 quarters · filed 2026-03-04 | $1.01M derived: sum of 3 quarters · filed 2026-08-06 | $1.40M 10-K · filed 2026-03-04 |
| 2025-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $673.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.06M 10-Q · filed 2025-11-12 | $1.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $334.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $722.00K 10-Q · filed 2026-08-06 | $1.10M derived: sum of 3 quarters · filed 2026-08-06 | $1.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $388.00K 10-Q · filed 2026-05-12 | $768.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.15M derived: sum of 3 quarters · filed 2026-05-12 | $1.52M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $759.00K derived: sum of 2 quarters · filed 2026-03-04 | $1.13M derived: sum of 3 quarters · filed 2026-03-04 | $1.50M 10-K · filed 2026-03-04 |
| 2024-09-30 | $379.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $749.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.13M 10-Q · filed 2025-11-12 | $1.48M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $370.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $746.00K 10-Q · filed 2025-08-07 | $1.10M derived: sum of 3 quarters · filed 2025-08-07 | $1.45M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $376.00K 10-Q · filed 2025-05-08 | $730.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.08M derived: sum of 3 quarters · filed 2025-05-08 | $1.41M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $703.00K derived: sum of 2 quarters · filed 2025-02-24 | $1.03M derived: sum of 3 quarters · filed 2025-02-24 | $1.18M 10-K · filed 2025-02-24 |
| 2023-09-30 | $349.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $680.00K derived: sum of 2 quarters · filed 2024-11-07 | $830.00K 10-Q · filed 2024-11-07 | $975.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $481.00K 10-Q · filed 2024-08-08 | $626.00K derived: sum of 3 quarters · filed 2024-08-08 | $769.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $150.00K 10-Q · filed 2024-05-14 | $295.00K derived: sum of 2 quarters · filed 2024-05-14 | $438.00K derived: sum of 3 quarters · filed 2024-05-14 | $577.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $145.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $288.00K derived: sum of 2 quarters · filed 2024-03-29 | $427.00K derived: sum of 3 quarters · filed 2024-03-29 | $493.00K 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $282.00K derived: sum of 2 quarters · filed 2023-11-08 | $348.00K 10-Q · filed 2023-11-08 | $396.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $205.00K 10-Q · filed 2023-08-08 | $253.00K derived: sum of 3 quarters · filed 2023-08-08 | $299.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $66.00K 10-Q · filed 2023-05-11 | $114.00K derived: sum of 2 quarters · filed 2023-05-11 | $160.00K derived: sum of 3 quarters · filed 2023-05-11 | $207.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $94.00K derived: sum of 2 quarters · filed 2023-03-23 | $141.00K derived: sum of 3 quarters · filed 2023-03-23 | $178.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $93.00K derived: sum of 2 quarters · filed 2022-11-10 | $130.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $84.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $37.00K 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |